Usefulness of 3′-deoxy-3′- 18F-fluorothymidine PET for predicting early response to chemoradiotherapy in head and neck cancer

Journal of Nuclear Medicine

Volumn 53, Issue 10, 2012, Pages 1521-1527

  Kishino, Takehito ^a   Hoshikawa, Hiroshi ^a   Nishiyama, Yoshihiro ^a   Yamamoto, Yuka ^a   Mori, Nozomu ^a  

^a KAGAWA UNIVERSITY   (Japan)

Author keywords

Chemoradiotherapy; Early evaluation; FDG PET; FLT PET; Head and neck

Indexed keywords

3' FLUOROTHYMIDINE F 18; ANTINEOPLASTIC AGENT; CISPLATIN; DOCETAXEL; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; NEDAPLATIN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; 3' FLUOROTHYMIDINE; DIAGNOSTIC AGENT;

ACCURACY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTINUOUS INFUSION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; TREATMENT RESPONSE; HEAD AND NECK TUMOR; METABOLISM; MIDDLE AGED; RETROSPECTIVE STUDY; SCINTISCANNING; SQUAMOUS CELL CARCINOMA; TIME; TRANSPORT AT THE CELLULAR LEVEL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL TRANSPORT; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DIDEOXYNUCLEOSIDES; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84867079875     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.111.099200     Document Type: Article

References (37)

1. Bourhis J, Eschwege F. Radiotherapy-chemotherapy combinations in head and neck squamous cell carcinoma: overview of randomized trials. Anticancer Res. 1996;16:2397-2402. (Pubitemid 26325422)
2. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
3. Kitagawa Y, Sano K, Nishizawa S, et al. FDG-PET for prediction of tumour aggressiveness and response to intra-arterial chemotherapy and radiotherapy in head and neck cancer. Eur J Nucl Med Mol Imaging. 2003;30:63-71. (Pubitemid 36692894)
4. 18F-fluorodeoxyglucose to predict pathologic response after induction chemotherapy and definitive chemoradiotherapy in head and neck cancer. Head Neck. 2004;26:890-896.
5. Isles MG, McConkey C, Mehanna HM. A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol. 2008;33:210-222. (Pubitemid 351799005)
6. Ware RE, Matthews JP, Hicks RJ, et al. Usefulness of fluorine-18 fluorodeoxyglucose positron emission tomography in patients with a residual structural abnormality after definitive treatment for squamous cell carcinoma of the head and neck. Head Neck. 2004;26:1008-1017. (Pubitemid 39601219)
7. Shields AF, Larson SM, Grunbaum Z, Graham MM. Short-term thymidine uptake in normal and neoplastic tissues: studies for PET. J Nucl Med. 1984;25:759-764. (Pubitemid 14087140)
8. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med. 2002;43:1210-1217. (Pubitemid 34988769)
9. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut. 2003;52:1602-1606. (Pubitemid 37363445)
10. 18F-FDG PET in esophageal cancer. J Nucl Med. 2005;46:400-404.
11. 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610-1616.
12. 18F]fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res. 2007;13:3552-3558.
13. Kenny L, Coombes RC, Vigushin DM, Al-Nahhas A, Shousha S, Aboagye EO. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F] fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging. 2007;34:1339-1347. (Pubitemid 47312585)
14. Pio BS, Park CK, Pietras R, et al. Usefulness of 3′-[F-18]fluoro- 3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol. 2006;8:36-42. (Pubitemid 44201576)
15. 18F-FLT PET during radiotherapy of esophageal squamous cell carcinoma: a pilot clinical study. J Nucl Med. 2010;51:528-534.
16. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med. 2010;51:866-874.
17. Sobin LH, Wittecind C. TNM Classification of Malignant Tumors. 6th ed. New York, NY: Wiley-Liss; 2002:19-56.
18. Kurita H, Yamamoto E, Nozaki S, Wada S, Furuta I, Kurashina K. Multicenter phase I trial of induction chemotherapy with docetaxel and nedaplatin for oral squamous cell carcinoma. Oral Oncol. 2004;40:1000-1006. (Pubitemid 39422785)
19. Fuwa N, Kodaira T, Kamata M, et al. Phase I study of combination chemotherapy with 5-fluorouracil (5-FU) and nedaplatin (NDP): adverse effects and recommended dose of NDP administered after 5-FU. Am J Clin Oncol. 2002;25:565-569. (Pubitemid 35453660)
20. Suzuki S, Ishikawa K. Safety and efficacy of S-1 chemotherapy in recurrent/metastatic head and neck cancer. J Infect Chemother. 2009;15:335-339.
21. 18F]FLT). J Radioanal Nucl Chem. 2000;243:843-846.
22. 3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281-287.
23. Mankoff DA, Shields AF, Krohn KA. PET imaging of cellular proliferation. Radiol Clin North Am. 2005;43:153-167. (Pubitemid 40326566)
24. 18F-fluorothymidine for monitoring tumor response to radiotherapy and photodynamic therapy in mice. J Nucl Med. 2004;45:1754-1758.
25. 18F]fluorothymidine PET to monitor early responses to radiation therapy in murine SCCVII tumors. Eur J Nucl Med Mol Imaging. 2006;33:412-419.
26. 3H-fluorothymidine using preclinical tumor models. Clin Cancer Res. 2006;12:4590-4597.
27. 18F)-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med. 2009;50:1028-1035.
28. 18F)-FDG in primary head and neck cancer correlates with survival. Nuklearmedizin. 2008;47:80-85.
29. Andrade RS, Heron DE, Degirmenci B, et al. Posttreatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys. 2006;65:1315-1322. (Pubitemid 44425218)
30. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo) radiotherapy in head and neck cancer. Head Neck. 2005;27:175-181. (Pubitemid 40315765)
31. Schöder H, Fury M, Lee N, Kraus D. PET monitoring of therapy response in head and neck squamous cell carcinoma. J Nucl Med. 2009;50(suppl):74S-88S.
32. Ryan WR, Fee WE Jr, Le Q, Pinto HA. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope. 2005;115:645-650. (Pubitemid 40530014)
33. 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med. 2007(suppl);48:58S-67S.
34. Malone JP, Gerberi MA, Vasireddy S, et al. Early prediction of response to chemoradiotherapy for head and neck cancer: reliability of restaging with combined positron emission tomography and computed tomography. Arch Otolaryngol Head Neck Surg. 2009;135:1119-1125.
35. Goerres GW, Schmid DT, Bandhauer F, et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2004;130:105-109. (Pubitemid 38095439)
36. Hoshikawa H, Kishino T, Nishiyama Y, Yamamoto Y, Yonezaki M, Mori N. Early prediction of local control in head and neck cancer after chemoradiotherapy by FDG PET. Nucl Med Commun. 2011;32:684-689.
37. 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2009;75:1098-1104.